Venture capital

The fragmentation of the venture capital market is hampering Europe’s tech industry, says Science|Business editor Richard L. Hudson

A venture capital company based in Switzerland and the Cayman Islands has raised €45 million, a record for a VC devoted exclusively to emerging nanotechnology.

In the lean years since the post-genomics bust, venture funding has been hard to come by for Europe’s biotech start-ups. Now they have polished up their business models, and valuations are low, attracting investors back in.